Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Lapatinib | Tykerb | 4.6 Fertility, pregnancy and lactation | Contraception in males and females | Mar,2023 |
| Erlotinib | Tarceva | 4.6 Fertility, pregnancy and lactation | Contraception in males and females | Mar,2023 |
| Erlotinib | Tarceva | 4.6 Fertility, pregnancy and lactation | Contraception in males and females | Mar,2023 |
| Decitabine | Decitabine Spc | 4.6 Fertility, pregnancy and lactation | Contraception in males and females | Mar,2023 |
| Dasatinib | Tykodas | 4.6 Fertility, pregnancy and lactation | "Contraception in males and females for 30 days after the last dose. Based on human experience, dasatinib is suspected to cause neural tube defects on the foetus when administered during pregnancy." | Mar,2023 |
| Cetuximab | Erbitux | 4.6 Fertility, pregnancy and lactation | Females: Advise females of reproductive potential to use effective contraception during treatment with cetuximab and for 2 months after the last dose of cetuximab. Adverse evnets in animals studies | Mar,2023 |